Efficacy of methenamine with methylthioninium in the treatment of dysuria: a randomized clinical study
- PMID: 37851092
- PMCID: PMC10756887
- DOI: 10.1007/s00192-023-05669-0
Efficacy of methenamine with methylthioninium in the treatment of dysuria: a randomized clinical study
Abstract
Introduction and hypothesis: Dysuria is a common symptom present in several urological and gynecological conditions. Management relies on the underlying disease but may require additional symptomatic treatment. This study evaluated the combination of methenamine 250 mg and methylthioninium chloride 20 mg in the treatment of dysuria versus phenazopyridine.
Methods: This was a multicenter, single-blind, randomized, superiority clinical trial, including individuals over 18 with dysuria and a score ≥ 5 points on the pre-treatment categorical scale for pain. The primary outcome was the proportion of participants presenting excellent clinical response within 24 h after treatment. Improvement up to 72 h, time to reach improvement, sustained healing, investigators' opinion, and safety were also evaluated.
Results: Three hundred and fifteen participants were evaluated. Demographic characteristics and symptoms of dysuria were comparable between groups at baseline. The difference in the excellent response rate between treatments within 24 h was 12.7% (95% CI 6.16, 19.21) for pain, 9.4% (95% CI 3.32, 15.39) for burning, and 12.7% (95% CI 6.37, 18.99) for burning on urination, all in favor of the test drug, which was also superior from 36 to 48 h. Treatments were similar concerning time to reach the absence of symptoms and in the percentage of participants with sustained healing after 72 h.
Conclusions: The association of methenamine with methylthioninium is superior to phenazopyridine in the treatment of dysuria.
Keywords: Dysuria; Methenamine; Non-antibiotic strategies; Pain; Urinary tract infections.
© 2023. The Author(s).
Conflict of interest statement
All authors were principal investigators of their respective research centers and received a fee for including patients in the study.
Figures
Similar articles
-
[Efficiency and safety of phenazopyridine for treatment of uncomplicated urinary tract infection: results of multi-center, randomized, placebo-controlled, clinical study].Urologiia. 2020 Jun;(3):15-21. Urologiia. 2020. PMID: 32597580 Clinical Trial. Russian.
-
Treatment of Recurrent Urinary Tract Infection Symptoms with Urinary Antiseptics Containing Methenamine and Methylene Blue: Analysis of Etiology and Treatment Outcomes.Res Rep Urol. 2020 Dec 15;12:639-649. doi: 10.2147/RRU.S279060. eCollection 2020. Res Rep Urol. 2020. PMID: 33365282 Free PMC article.
-
[Current opportunities for symptomatic treatment of dysuria].Urologiia. 2019 Jun;(2):97-102. Urologiia. 2019. PMID: 31162909 Review. Russian.
-
[Phenazopyridine and fosfomycin for the acute cystitis treatment: results of multicenter randomized study].Urologiia. 2021 Jun;(3):20-27. Urologiia. 2021. PMID: 34251097 Clinical Trial. Russian.
-
Strategies for the removal of short-term indwelling urethral catheters in adults.Cochrane Database Syst Rev. 2021 Jun 29;6(6):CD004011. doi: 10.1002/14651858.CD004011.pub4. Cochrane Database Syst Rev. 2021. PMID: 34184246 Free PMC article.
References
-
- Mehta P, Leslie SW, Reddivari AKR. Dysuria. StatPearls. 2022. https://www.ncbi.nlm.nih.gov/books/NBK549918/. Accessed 15 Mar 2023.
-
- Arroyo JCL, Moraes RO, Silva EF, Sá OR, França N. Prevalência de infecção do trato urinário entre pacientes atendidos na Unidade de Pronto Atendimento (UPA) no município de Passos – MG [Prevalence of Urinary Tract Infection Among Patients Attended at the Emergency Care Unit (ECU) at the Municipality of Passos – MG] Rev Mult Psic. 2020;54:603–616.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources